Goldman Sachs Group Inc Chemo Centryx, Inc. Transaction History

Goldman Sachs Group Inc

$613 Billion
Q4 2024

Shares

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 May 14, 2024	BUY	$22.17 - $51.8 $114 Million - $266 Million	5,138,232 Added 1074.79%	5,616,301 $290 Million
Q3 2022 Nov 10, 2022	BUY	$22.17 - $51.8 $114 Million - $266 Million	5,138,232 Added 1074.79%	5,616,301 $290 Million
Q2 2022 May 14, 2024	BUY	$15.36 - $27.51 $7.34 Million - $13.2 Million	478,069 New	478,069 $11.8 Million
Q2 2022 Aug 15, 2022	BUY	$15.36 - $27.51 $1.41 Million - $2.53 Million	92,086 Added 23.86%	478,069 $11.8 Million
Q1 2022 May 16, 2022	SELL	$22.22 - $39.12 $3.36 Million - $5.92 Million	-151,308 Reduced 28.16%	385,983 $9.68 Million
Q4 2021 Feb 14, 2022	BUY	$18.38 - $40.5 $7.51 Million - $16.6 Million	408,850 Added 318.32%	537,291 $19.6 Million
Q3 2021 Nov 10, 2021	BUY	$13.18 - $19.83 $1.69 Million - $2.55 Million	128,441 New	128,441 $2.2 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.